How to Get Repatha (Evolocumab) in Nebraska

What Is Repatha and Why Is It Prescribed?

Repatha is a fully human monoclonal antibody that inhibits PCSK9, a protein that degrades LDL receptors on hepatocytes. Blocking PCSK9 keeps more receptors available on liver cells, which clears more LDL-C from the bloodstream. The FDA approved evolocumab in August 2015 for adults with heterozygous familial hypercholesterolemia (HeFH), homozygous familial hypercholesterolemia (HoFH), and established atherosclerotic cardiovascular disease (ASCVD) who require additional LDL-C lowering beyond maximally tolerated statin therapy [1].

The FOURIER trial (N=27,564) published in the New England Journal of Medicine in 2017 demonstrated that evolocumab reduced LDL-C by 59% from baseline (median baseline 92 mg/dL, median on-treatment 30 mg/dL) and cut the composite of cardiovascular death, myocardial infarction, or stroke by a relative 20% versus placebo over a median 2.2-year follow-up (hazard ratio 0.80 to 95% CI 0.73 to 0.88, P<0.001) [2]. That single trial established the cardiovascular outcomes evidence that most Nebraska insurers now require for prior authorization approval.

The American College of Cardiology and American Heart Association 2018 cholesterol guidelines state: "In patients with very high-risk ASCVD, use of a PCSK9 inhibitor is recommended when LDL-C remains 70 mg/dL or higher despite maximally tolerated statin and ezetimibe therapy" [3]. Nebraska prescribers and patients can cite this language directly in prior authorization appeals.

Dosing is straightforward. The 140 mg prefilled SureClick autoinjector or prefilled syringe is administered subcutaneously every two weeks. Alternatively, three consecutive 140 mg injections given on the same day once monthly (totaling 420 mg) may fit patients who prefer a monthly schedule [1]. Both regimens produce equivalent LDL-C lowering at steady state.

Who Can Prescribe Repatha in Nebraska?

Any Nebraska-licensed prescriber with authority to write Schedule and non-scheduled prescriptions may prescribe evolocumab. That includes physicians (MD and DO), nurse practitioners (NPs operating under Nebraska Nurse Practice Act Title 172, Chapter 95), and physician assistants (PAs licensed under Nebraska statute 38-2046) [4]. Nebraska does not require a specialist designation for evolocumab prescriptions, though many commercial insurers ask for documentation from a cardiologist or lipidologist during prior authorization review.

Telehealth prescribing is explicitly permitted in Nebraska. The Nebraska Telehealth Act (Neb. Rev. Stat. sections 71-8501 through 71-8514) requires that a valid provider-patient relationship be established before prescribing, but that relationship can be formed through a synchronous audiovisual visit [5]. Nebraska also adheres to the Interstate Medical Licensure Compact, which means out-of-state physicians who hold a compact license covering Nebraska may prescribe to Nebraska patients via telehealth [6].

A practical three-step framework for Nebraska patients seeking a telehealth Repatha prescription:

1. Complete a synchronous video visit with a compact-licensed prescriber. Bring fasting lipid panel results dated within the past 90 days, a list of current statins tried, and any prior statin intolerance documentation.
2. Authorize the prescriber to submit a prior authorization request to your insurer on your behalf, including the FOURIER outcomes data [2] and your most recent LDL-C reading.
3. Designate a Nebraska-licensed specialty pharmacy or your insurer's preferred mail-order pharmacy to dispense. Amgen's Repatha patient support program (Repatha360) can assist with specialty pharmacy coordination once authorization is in hand.

What Labs Are Needed Before Starting Repatha in Nebraska?

A fasting lipid panel is the minimum laboratory requirement before any Nebraska provider will prescribe evolocumab. Fasting for 9 to 12 hours before the draw gives the most accurate LDL-C, triglyceride, and HDL-C values [7]. Most insurers and the ACC/AHA guidelines require documentation that LDL-C remains at or above 70 mg/dL (for established ASCVD) or at or above 100 mg/dL (for HeFH without ASCVD) despite maximally tolerated statin therapy [3].

Beyond the lipid panel, Nebraska prescribers typically order or review:

• A comprehensive metabolic panel (CMP) to assess hepatic function, because severe hepatic impairment (Child-Pugh C) is a relative contraindication listed in the Repatha prescribing information [1].
• A thyroid-stimulating hormone (TSH) level if secondary dyslipidemia from hypothyroidism has not been previously excluded.
• Documentation of prior statin therapy, including the name, dose, and duration of at least one high-intensity statin (rosuvastatin 20 to 40 mg or atorvastatin 40 to 80 mg per the ACC/AHA intensity classification) [3].

The GLAGOV trial (N=968) showed that patients with a mean baseline LDL-C of 87.8 mg/dL who received evolocumab for 76 weeks achieved a mean LDL-C of 36.6 mg/dL and demonstrated 0.95% regression in percent atheroma volume versus a 0.05% progression in the placebo group (P<0.001) [8]. That imaging evidence supports aggressive LDL-C lowering, which is why most Nebraska cardiologists now order a baseline lipid panel and repeat it 4 to 12 weeks after the first injection to confirm the expected 50 to 60% LDL-C reduction [1].

Labs should be sent to a CLIA-certified laboratory. Many Nebraska telehealth platforms partner with Quest Diagnostics or LabCorp locations throughout Omaha, Lincoln, Grand Island, Kearney, and Scottsbluff so patients can complete draws locally before their video visit [9].

How Prior Authorization Works for Repatha in Nebraska

Prior authorization (PA) is the single biggest source of delay for Nebraska patients. Commercial insurers covering Nebraska residents, including Blue Cross and Blue Shield of Nebraska, Medica, and UnitedHealthcare plans offered through the Nebraska exchange, each maintain their own PA criteria, but they generally align with the clinical evidence thresholds from ACC/AHA guidelines [3].

A complete PA submission package typically includes:

• The prescribing provider's signed letter of medical necessity citing the FOURIER outcomes data [2] and the patient's most recent LDL-C on maximally tolerated statin therapy.
• Lab results showing LDL-C at or above the insurer's threshold (most commonly 70 mg/dL for ASCVD, 100 mg/dL for HeFH).
• Documentation of at least two statins tried at maximally tolerated doses, with dates and dosages, or documentation of statin intolerance with a clinical note describing the adverse effect (most commonly myalgia confirmed by CK elevation or rechallenge failure) [10].
• For HeFH: genetic testing confirming a pathogenic mutation in LDLR, APOB, or PCSK9, or a clinical diagnosis using the Dutch Lipid Clinic Network (DLCN) criteria score of 6 or greater [11].

Nebraska Medicaid does not currently cover Repatha for either familial hypercholesterolemia or established ASCVD indications as of 2025. Patients on Medicaid should ask their prescriber about the Amgen REPATHA360 Patient Support Program, which includes a co-pay card for commercially insured patients (reducing out-of-pocket cost to as low as $0 per month with eligible insurance) and an uninsured patient assistance program [12].

When a PA is denied, Nebraska law (Neb. Rev. Stat. section 44-7301) gives insured patients the right to an internal appeal within 30 days of the denial and an external independent review if the internal appeal is unsuccessful. The ACC/AHA guideline language from 2018 [3] combined with the FOURIER hazard ratio data [2] forms the strongest foundation for a first-level appeal letter.

Pharmacy Access for Repatha in Nebraska

Repatha is classified as a specialty medication and is dispensed through specialty pharmacies rather than standard retail chains in most cases. Nebraska-licensed specialty pharmacies that can fill evolocumab include Omaha-based facilities accredited by URAC or the Accreditation Commission for Health Care (ACHC). Patients in rural Nebraska, including the Sandhills, Panhandle, and northeast corridor, can receive Repatha via temperature-controlled overnight shipping from any specialty pharmacy licensed to ship into Nebraska [13].

503A compounding pharmacies licensed in Nebraska may also prepare evolocumab formulations, though compounded PCSK9 inhibitors are far less common than compounded small molecules because monoclonal antibody compounding requires specialized sterile manufacturing capacity. A patient considering a 503A compounded version should verify the pharmacy holds a Nebraska Board of Pharmacy 503A license, uses FDA-registered bulk drug substances, and provides a certificate of analysis for each batch. The FDA's current thinking on compounding standards for biologics is outlined in its guidance documents for 503A and 503B facilities [14].

Amgen offers a specialty pharmacy locator through the Repatha360 program. Patients with a confirmed PA approval can call 1-844-REPATHA to have their prescription routed directly to a network specialty pharmacy with home delivery available throughout Nebraska [12].

How Long Does It Take to Receive Repatha in Nebraska?

The timeline from a completed office or telehealth visit to first injection has several stages, each with its own duration. A typical Nebraska patient should expect:

• Telehealth or in-person visit and lab completion: same day to 3 days.
• PA submission by prescriber: 1 to 2 business days after visit.
• Insurer PA decision (standard review): 3 to 14 business days under Nebraska insurance law [15].
• Specialty pharmacy processing and shipment: 2 to 5 business days after PA approval.
• Total estimated time from visit to first dose: 10 to 21 days for most commercially insured patients.

Urgent or expedited PA review is available for patients with recent acute coronary syndrome. Nebraska insurers must render urgent-review decisions within 72 hours under state law [15]. After the PA is approved, the specialty pharmacy ships Repatha in an insulated cooler; the autoinjector must be stored in the refrigerator at 36 to 46 degrees Fahrenheit and should not be frozen [1].

A 2023 analysis published in the Journal of the American College of Cardiology found that among 14,236 PCSK9 inhibitor PA requests across multiple US health systems, 61% were ultimately approved on first or second attempt, and the median time from PA submission to approval was 9 days (interquartile range 4 to 18 days) [16]. Patients who submitted complete documentation on the first attempt had a 74% first-attempt approval rate versus 43% for incomplete submissions, which underscores the value of preparing a thorough PA package before submission.

Transferring an Existing Repatha Prescription to Nebraska

Patients relocating to Nebraska from another state can transfer their evolocumab prescription in two ways. First, if the original prescriber holds a Nebraska medical license or a compact license covering Nebraska, they can continue prescribing and route the PA to a Nebraska-licensed specialty pharmacy [6]. Second, the patient can establish care with a Nebraska-licensed provider, who will typically request records from the prior prescriber, confirm the current LDL-C on a repeat lipid panel, and submit a new PA to the Nebraska insurer [4].

Most Nebraska insurers require a new PA when a patient changes insurance plans, even if a valid PA exists with a prior insurer. The re-authorization process follows the same documentation pathway described above [3]. Patients should ask their new Nebraska insurer for the formulary tier and PA criteria for Repatha before their first office visit to ensure the visit documentation addresses every criterion.

One practical note: Nebraska is not part of every specialty pharmacy network, and some out-of-state pharmacies that previously dispensed Repatha may not hold a Nebraska non-resident pharmacy permit. Confirming the dispensing pharmacy's Nebraska licensure status with the Nebraska Board of Pharmacy (online license verification at dhhs.ne.gov) prevents shipment delays after PA approval [13].

Safety Profile and Monitoring After Starting Repatha

Evolocumab has a favorable safety record in large randomized trials. In FOURIER (N=27,564, median follow-up 2.2 years), rates of serious adverse events did not differ significantly between the evolocumab and placebo arms (P<0.001 for cardiovascular benefit; injection-site reactions occurred in 2.1% of evolocumab patients versus 1.6% placebo) [2]. New-onset diabetes, a concern with statin intensification, was not increased with evolocumab compared to placebo in either FOURIER or the OSLER-1 and OSLER-2 open-label extension studies [17].

The EBBINGHAUS substudy of FOURIER (N=1,974) specifically evaluated cognitive function using the Cambridge Neuropsychological Test Automated Battery (CANTAB) and found no significant difference in executive function, working memory, or processing speed between evolocumab and placebo groups at 19 months, which addressed early regulatory concerns about very low LDL-C and neurocognitive effects [18].

Nebraska prescribers generally follow a monitoring schedule of:

• Repeat fasting lipid panel 4 to 12 weeks after the first dose to confirm the expected 50 to 60% LDL-C reduction [1].
• Annual lipid panel and clinical review thereafter.
• CMP at baseline and annually for patients with pre-existing hepatic disease.

Injection-site rotation between the abdomen, thigh, and upper arm reduces local reactions. Patients should allow the autoinjector to reach room temperature for at least 30 minutes before injection, and should not inject into skin that is tender, bruised, red, or hard [1].

Cost and Patient Assistance in Nebraska

The wholesale acquisition cost of Repatha is approximately $700 per month for the every-two-week dosing schedule. With commercial insurance PA approval, most patients pay $0 to $50 per month using the Amgen co-pay card (eligibility restrictions apply; Medicaid beneficiaries are excluded by law from manufacturer co-pay programs under the federal Anti-Kickback Statute) [12].

Uninsured Nebraska patients may qualify for the Amgen Safety Net Foundation, which provides Repatha at no cost to patients with household income at or below 500% of the federal poverty level. Applications are processed through the Repatha360 program at 1-844-REPATHA [12].

A 2021 cost-effectiveness analysis in Circulation found that evolocumab became cost-effective (cost per quality-adjusted life-year below $100,000) at a net price threshold of approximately $4,500 per year, a price point that some commercial contracts have reached through manufacturer rebates [19]. This analysis used FOURIER event-rate data [2] as its primary input and is frequently cited in PA appeal letters arguing that coverage is clinically and economically appropriate.